Oric® Pharmaceuticals在2025年ESMO亚洲大会上宣布Enozertinib(Oric-114)关于EGFR非典型和EGFR外显子20非小细胞肺癌的最新口头报告。
Oric® Pharmaceuticals在2025年ESMO亚洲大会上宣布Enozertinib(Oric-114)关于EGFR非典型和EGFR外显子20非小细胞肺癌的最新口头报告。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.